CO4780020A1 - Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina - Google Patents

Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina

Info

Publication number
CO4780020A1
CO4780020A1 CO97010841A CO97010841A CO4780020A1 CO 4780020 A1 CO4780020 A1 CO 4780020A1 CO 97010841 A CO97010841 A CO 97010841A CO 97010841 A CO97010841 A CO 97010841A CO 4780020 A1 CO4780020 A1 CO 4780020A1
Authority
CO
Colombia
Prior art keywords
acid
prolonged
release
formulation according
mizolastine
Prior art date
Application number
CO97010841A
Other languages
English (en)
Inventor
Chariot Maryvonne
Gareth Lewis
Jean Montel
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of CO4780020A1 publication Critical patent/CO4780020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación farmacéutica de liberación prolongada, quecontienen mizolastina, caracterizada porque comprende un núcleo formado por un comprimido de liberación prolongada que comprende mizolastina asociada con una matriz grasa y con un ácido orgánico estando dicho comprimido, recubierto.formulación farmacéutica de liberación prolongada de acuerdo con la reivindicación 1, caracterizada porque la relación ponderal entre la mizolastina y el ácido orgánico está comprendida entre 0,3 y 1.Formulación farmacéutica de liberación prolongada de acuerdo con una cualquiera de las reivindicaciones 1 y 2 caracterizada porque la matriz grasa es preparada con aceite de ricino hidrogenado o con lecitinas hidrogenadas o con ácidos grasos de cadena larga o con triglicéridos esterificados con ácidos grasos de cadena mediana.Formulación farmacéutica de liberacióm prolongada de acuerdo con una cualquiera de las reivindicaciones 1 a 3, caracterizada porque el ácido orgánico es elegido entre los ácidos maleico, ácido tartárico, ácido málico, ácido fumárico, ácido cítrico, ácido adípico, ácido succínico, bajo forma de racematos o de isómeros.Formulación farmacéutica de liberación prolongada de acuerdo con una cualquiera de las reivindicaciones 1 a 4, caracterizada porque el ácido orgánico es el ácido L-tartárico.Formulación farmacéutica de liberación prolongada de acuerdo con la reivindicación 5, caracterizada porque la relación entre la mizolastina y el ácido L-tartárico, es de 0,5.
CO97010841A 1996-03-04 1997-02-28 Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina CO4780020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
CO4780020A1 true CO4780020A1 (es) 1999-05-26

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97010841A CO4780020A1 (es) 1996-03-04 1997-02-28 Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina

Country Status (35)

Country Link
US (2) US6165507A (es)
EP (1) EP0906101B1 (es)
JP (2) JP2000512617A (es)
KR (1) KR100369888B1 (es)
CN (1) CN1112929C (es)
AR (1) AR006082A1 (es)
AT (1) ATE219365T1 (es)
AU (1) AU725494B2 (es)
BG (1) BG63451B1 (es)
BR (1) BR9707827A (es)
CA (1) CA2247405C (es)
CO (1) CO4780020A1 (es)
CY (1) CY2293B1 (es)
CZ (1) CZ291418B6 (es)
DE (1) DE69713505T2 (es)
DK (1) DK0906101T3 (es)
EE (1) EE03511B1 (es)
ES (1) ES2177942T3 (es)
FR (1) FR2745500B1 (es)
HK (1) HK1017999A1 (es)
HU (1) HU227472B1 (es)
IL (1) IL126050A (es)
IN (1) IN187739B (es)
NO (1) NO315841B1 (es)
NZ (1) NZ331947A (es)
OA (1) OA10854A (es)
PL (1) PL189813B1 (es)
PT (1) PT906101E (es)
RU (1) RU2173997C2 (es)
SK (1) SK282112B6 (es)
TR (1) TR199801574T2 (es)
TW (1) TW491711B (es)
UA (1) UA49004C2 (es)
WO (1) WO1997032584A1 (es)
ZA (1) ZA971830B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
WO2002028181A1 (en) * 2000-10-02 2002-04-11 Usv Limited Sustained release pharmaceutical compositions containing metformin and method of its production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2004078164A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP5295356B2 (ja) 2008-07-28 2013-09-18 武田薬品工業株式会社 医薬組成物
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
ATE219365T1 (de) 2002-07-15
CA2247405A1 (en) 1997-09-12
AU725494B2 (en) 2000-10-12
CZ291418B6 (cs) 2003-03-12
HU227472B1 (en) 2011-07-28
ZA971830B (en) 1997-09-04
CN1212624A (zh) 1999-03-31
NO984035D0 (no) 1998-09-02
DK0906101T3 (da) 2002-10-14
WO1997032584A1 (fr) 1997-09-12
HUP9902458A3 (en) 2002-11-28
TR199801574T2 (xx) 1998-11-23
HK1017999A1 (en) 1999-12-10
BG63451B1 (bg) 2002-02-28
CZ279198A3 (cs) 1999-01-13
FR2745500B1 (fr) 1998-04-03
FR2745500A1 (fr) 1997-09-05
EP0906101A1 (fr) 1999-04-07
PL189813B1 (pl) 2005-09-30
ES2177942T3 (es) 2002-12-16
IN187739B (es) 2002-06-15
AU1930097A (en) 1997-09-22
PT906101E (pt) 2002-09-30
OA10854A (fr) 2003-02-05
KR100369888B1 (ko) 2003-05-17
CN1112929C (zh) 2003-07-02
TW491711B (en) 2002-06-21
PL328763A1 (en) 1999-02-15
DE69713505T2 (de) 2003-02-13
BG102692A (en) 1999-04-30
EE03511B1 (et) 2001-10-15
US6165507A (en) 2000-12-26
JP2007182451A (ja) 2007-07-19
DE69713505D1 (de) 2002-07-25
IL126050A (en) 2004-05-12
NO984035L (no) 1998-10-22
IL126050A0 (en) 1999-05-09
RU2173997C2 (ru) 2001-09-27
SK121098A3 (en) 1999-01-11
UA49004C2 (uk) 2002-09-16
KR19990087387A (ko) 1999-12-27
CY2293B1 (en) 2003-07-04
BR9707827A (pt) 1999-07-27
JP2000512617A (ja) 2000-09-26
SK282112B6 (sk) 2001-11-06
EP0906101B1 (fr) 2002-06-19
NO315841B1 (no) 2003-11-03
HUP9902458A2 (hu) 2000-05-28
EE9800275A (et) 1999-02-15
US20050202089A1 (en) 2005-09-15
AR006082A1 (es) 1999-08-11
CA2247405C (en) 2004-04-20
NZ331947A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
CO4780020A1 (es) Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina
PA8499101A1 (es) Composicion de ovulos intravaginales de clindamicina
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
SV1995000002A (es) Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
HRP20030493B1 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
DE69720787D1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
ES2183555T3 (es) Formulaciones efervescentes.
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
ES2174080T3 (es) Vehiculos de principios activos a base de agentes tensioactivos no ionicos y sus aplicaciones particularmente en los ambitos alimentario, cosmetico y farmaceutico.
CY1108914T1 (el) Μητρα για παρατεταμενη, αμεταβλητη και ανεξαρτητη απελευθερωση δραστικων ενωσεων
DE69419422T2 (de) Gesunde fette für brotaufstrich
AR068015A2 (es) Microgranulos de sulfato de morfina procedimiento para su preparacion y composicion que los contiene
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CO4910117A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
DK0657164T3 (da) Farmaceutiske præparater indeholdende staurosporinderivater og et polyalkylenglycolglycerid
RU98118019A (ru) Фармацевтические препараты замедленного высвобождения, содержащие мизоластин
ES2166577T3 (es) Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos.
ES2051827T3 (es) Una composicion farmaceutica que contiene aceite de ricino polietoxilado.
CO4700448A1 (es) Composiciones farmaceuticas
DK0982035T3 (da) Cyclosporinpræparater